Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors

Conclusions: An anti-PD-1 antibody produced objective responses in approximately 25% patients with various solid tumors, demonstrating that it could improve the immune system in vivo.

Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Chang Jiang, Xiuyu Cai, Hongxia Zhang, Xiaojun Xia, Bei Zhang, Liangping Xia Tags: Research Paper Source Type: research